All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference for all purposes.
This disclosure relates generally to methods and systems for transferring power transcutaneously, and in certain respects, using a plurality of conductors to transfer power.
Implantable medical devices such as pacemakers, ventricular assist devices (VADs), spinal cord stimulation (SCS) devices, and deep brain stimulation (DBS) devices require electric power to operate. That power may be provided, for example, by an internal battery (e.g., for pacemakers, SCS devices, and DBS devices), AC mains, or an external battery (e.g., for VADs).
Implanted batteries generally limit the amount of power that can be delivered to the implanted device. Further, implanted batteries may require surgical replacements. More recently, there has been a focus on developing systems for wirelessly transferring power to implanted batteries. Such systems, however, may be relatively inefficient, and have yet to be realized for high-powered devices such as VADs.
External batteries typically require a wired electrical connection to the implanted device that passes through the skin of the patient. In the example of VADs, percutaneous cables used to transfer power, data, or both through the skin are referred to as percutaneous drivelines. For such drivelines, it is desirable to provide a safe, relatively small connection through the skin. Further, it is desirable to prevent displacement of such drivelines.
Accordingly, it would be desirable to provide a transcutaneous power transfer system that provides transfer of power and/or data from the outside of the body to the inside of the body. There is a desire to improve existing mechanisms for transfer of power and/or data through the skin of a patient.
In one embodiment, a system for supplying power transcutaneously to an implantable device implanted within a subject is provided. The system includes an external connector including one of a microneedle array and a microwire holder. The system further includes a power cable electrically coupled to the external connector and configured to supply power to the one of the microneedle array and the microwire holder from an external power source, and an internal connector configured to be implanted within the subject and electrically coupled to the implantable device, the internal connector including the other of the microneedle array and the microwire holder. The microneedle array includes a plurality of electrically conductive microneedles, the microwire holder includes a plurality of electrical contacts, and the microwire holder is configured to engage the microneedle array such that the plurality of electrically conductive microneedles extend through the skin of the subject and electrically couple to the plurality of electrical contacts. In various embodiments, the conductive microneedles are relatively thin structures having a conductive wire or element. In various embodiments, the microneedles are formed of a needle-like structure loaded with a conductive wire. The needle-like structure may an insulative body.
In one embodiment, a system for supplying power transcutaneously to an implantable device implanted within a subject is provided. The system includes a first microconductor configured to extend through the subject's skin, a second microconductor configured to extend through the subject's skin, wherein the first microconductor and the second microconductor are configured to receive and conduct power generated by an external power source, and a control unit configured to be implanted within the subject. The control unit includes a housing, a first electrical contact configured to electrically couple to the first microconductor, a second electrical contact configured to electrically couple to the second microconductor, control circuitry positioned within the housing and electrically coupled to the first and second electrical contacts, the control circuitry configured to control operation of the implantable device, and a driveline connector electrically coupled to the control circuitry, the driveline connector configured to transfer power and control signals to the implantable device through a driveline extending between the driveline connector and the implantable device.
In one embodiment, a method of implanting a transcutaneous power transfer system in a subject is provided, the transcutaneous power transfer system operable to supply power transcutaneously to an implantable device in the subject. The method includes implanting an internal connector within the subject, the internal connector including a microwire holder that includes a plurality of electrical contacts, connecting an external connector to the internal connector by inserting a plurality of electrically conductive microneedles through the skin of the subject such that the plurality of electrically conductive microneedles electrically couple to the plurality of electrical contacts, connecting a power cable to the external connector, and supplying power to the plurality of electrically conductive microneedles from an external power source using the power cable.
In one embodiment, a method of implanting a transcutaneous power transfer system in a subject is provided, the transcutaneous power transfer system operable to supply power transcutaneously to an implantable device in the subject. The method includes implanting a control unit within the subject, the control unit including a housing, a first electrical contact, a second electrical contact, and control circuitry configured to control operation of the implantable device, inserting a first microconductor through the skin of the subject such that the first microconductor electrically contacts the first electrical contact, inserting a second microconductor through the skin of the subject such that the second microconductor electrically contacts the second electrical contact, and supplying power to the first and second microconductors from an external power source.
In one embodiment, a method of forming a connection between an external connector and an internal connector in a transcutaneous power transfer system is provided. The method includes piercing skin of a subject with plurality of electrically conductive microneedles formed on the external connector, and placing the plurality of electrically conductive microneedles in contact with a plurality of electrical contacts formed on the internal connector.
In one embodiment, a system incorporating any of the above features is provided.
In one embodiment, a device incorporating any of the above features is provided.
Features that are described and/or illustrated with respect to one embodiment may be used in the same way or in a similar way in one or more other embodiments and/or in combination with or instead of the features of the other embodiments. That is, any feature described herein may be used in any of the embodiments described herein.
The novel features of the disclosure are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
In the description that follows, like components have been given the same reference numerals, regardless of whether they are shown in different embodiments. To illustrate an embodiment(s) of the present disclosure in a clear and concise manner, the drawings may not necessarily be to scale and certain features may be shown in somewhat schematic form. Features that are described and/or illustrated with respect to one embodiment may be used in the same way or in a similar way in one or more other embodiments and/or in combination with or instead of the features of the other embodiments.
The systems and methods in certain embodiments include a transcutaneous power transfer system. The transcutaneous power transfer system includes electrical connections that pass through the subject's skin, but that are relatively small. In some embodiments, an electrical connection is formed using a plurality of parallel sub-passages that, when taken together, provide enough power to drive an implanted medical device or recharge an implanted battery. Each sub-passage is on a micro-scale such that it passes through pores already present in the skin, reducing irritation and risk of infection to the subject.
Turning now to
External connector 104 includes a microneedle array 110 for electrically and physically coupling to internal connector 106. Specifically, microneedle array 110 includes a plurality of electrically conductive microneedles 112. Each microneedle 112 includes a rigid or semi-rigid conductive core material coated with an insulation material (e.g., Tefzel ETFE). The conductive core material is exposed at a tip of microneedle 112. For example, each microneedle 112 may include a metal alloy coated with a thin polymer insulation material. In this embodiment, microneedles 112 are evenly spaced from one another, and may be arranged in a one-dimensional array (i.e., spaced along a line) or a two-dimensional grid. Microneedles 112 include a positive set of microneedles and a negative set of microneedles. To couple to internal connector 106, microneedles 112 pierce skin 102 (e.g., passing through pores in skin 102).
In various respects, the term “microneedle” refers to a thin-diameter or needle-like structure with a conductive element, and in certain respects a conductive structure configured for piercing tissue or the skin. One of skill will appreciate from the description herein that a variety of assemblies may be used to form the microneedles depending on the application. For example, the conductive microneedles may be formed entirely of conductive materials. In another example, the microneedle includes an insulative body and a conductive element. The microneedle may be formed of an insulator hollow body loaded with a conductive material. Other structures will be further understood from the following description.
Further, internal connector 106 includes a microwire holder 114 that has a plurality of electrical contacts 116. Electrical contacts 116 include a positive set of electrical contacts and a negative set of electrical contacts. To transfer power, external connector 104 is positioned relative to internal connector 106 such that microneedles 112 extend through the skin 102 and engage electrical contacts 116, electrically coupling external connector 104 to internal connector 106. Specifically, external connector 104 is positioned such that the positive set of microneedles engages the positive set of electrical contacts and the negative set of microneedles engages the negative set of electrical contacts.
In an alternative embodiment, external connector 104 includes microwire holder 114 and internal connector 106 includes microneedle array 110. Accordingly, instead of extending from the outside of a subject's body to the inside of the subject's body, microneedles 112 extend from the inside of the subject's body to the outside of the subject's body. In such an embodiment, microwire holder 114 is external to the subject's body (instead of subcutaneous), and receives microneedles 112 extending from internal connector 106.
In this embodiment, system 100 further includes a power cable 120 that supplies power to external connector 104 from an external power source (not shown). The power source may include external batteries, AC mains, or an external controller. Power cable 120 includes a plug 122 that engages an electrical socket 124 on external connector 104. In some embodiments, plug 122 magnetically couples to electrical socket 124. Accordingly, when a sufficient force is exerted on power cable 120, plug 122 disengages from electrical socket 124 without pulling external connector 104 away from internal connector 106.
As shown in
In this embodiment, internal connector 106 includes an anchor 130 for securing the position of internal connector 106 within the body. For example, as will be appreciated by those of skill in the art, anchor 130 may anchor internal connector 104 to a bone (e.g., a rib) of the subject. Alternatively, anchor 130 may be any suitable anchoring device. For example, anchor 130 may be implemented using nitinol hooks or sutures that engage tissue of the subject. Further, tissue ingrowth around internal connector 106 may be used to anchor internal connector 106. One will appreciate that internal connector 106 may include a variety of tissue or skin anchors 130 depending on the application. In various embodiments, internal connector 106 is anchored to a bone. The optional anchoring may be used to mitigate the risk of migration of internal connector 106 over time. External connector 104 and internal connector 106 may be left in place for a relatively long period of time and/or may be replaced periodically. In such cases, there may be the possibility that internal connector 106 moves from its implant location and makes it harder for internal connector 106 to be located and/or accessed. If internal connector 106 migrates too much, there may also be the risk of the connection to external connector 104 becoming loose. In certain applications and implant locations, however, the risk of migration is relatively low and tolerable even without anchoring structures. In some embodiments, external connector 104 and/or internal connector 106 may include safety mechanisms to prevent an overcurrent condition if external connector 104 and/or internal connector 106 are incorrectly connected to one another.
As shown in
In some embodiments, external connector 104 is easily detachable from internal connector 106. Further, external connector 104 and/or internal connector 106 may include safety mechanisms to prevent an overcurrent condition if external connector 104 and internal connector 106 are incorrectly connected to one another.
For example, in some embodiments, an external power source (not shown in
In some embodiments, the safety mechanism includes fuse circuitry that breaks when an overcurrent condition occurs. Specifically, the fuse circuitry measures a total resistance between a positive end and a negative end of the fuse circuitry. If the measured total resistance is below a first predetermined threshold, the circuit breaks (e.g., short circuits). Further, if the measured total resistance is greater than a second predetermined threshold, a loose connection/disconnection alert is generated. This fuse circuitry may be located, for example, outside of the subject (e.g., within power cable 120), and may be powered by an external power source. Alternatively, the fuse circuitry may be located within the subject, and may be powered by a subcutaneous device battery.
In some embodiments, the safety mechanism includes an analog switch for each electrical contact 116. For example, each analog switch could be coupled to a resistor (e.g., of approximately 0.1 Ohm). If there is an overcurrent and/or a voltage drop exceeding a predetermined threshold (e.g., 100 mV) for only a few electrical contacts 116 (e.g., one or two electrical contacts 116), those electrical contacts 116 can be switched off, allowing the remaining electrical contacts 116 to continue supplying power to the implanted device. However, if more electrical contacts 116 demonstrate an overcurrent and/or a voltage drop exceeding the predetermined threshold, power may be disconnected completely.
By using microneedle array 110 and microwire holder 114, system 100 prevents overheating at the connection between external connector 104 and internal connector 106. Heating occurs due to the flow of current through resistive wires. The flow of current produces generation of power (i.e., P=I2R) which subsequently results in a temperature rise. As temperature increases, power dissipation by convention, conduction, and radiation also increases. Equilibrium is reached when power generation equals power dissipation. Assuming that radiation is the only source of power dissipation, the rise in temperature for current I is given by:
where ρ is the resistivity of the material, l is the length of the wire, d is the diameter of the wire, n is the number of wires in the connector, σ is the Stefan-boltzman constant, TR=300K is the room temperature, and ϵ is emissivity.
An exemplary VAD may require approximately 7 Watts of power at 12 Volts, which results in a current flow of 0.583 Amps. This gives n=307 for a ΔT=0.1 C using copper wire (ρ=1.68 e−8 Ωm, ϵ=0.04) with d=10 μm and l=1 mm. As the radiation is taken as the only mechanism of power dissipation, n=307 should result in an even lower change in temperature. Further, d up to 40 μm (skin pore size is approximately 50 μm) may be used if needed. Also, using oxidation, the emissivity of copper can be increased to 0.8 if needed. If both of these adjustments are made together, n=1 (i.e., a single microneedle 112) results in a temperature rise of 0.1 C. Notably, these figures may be conservative examples, as they only consider radiation as a heat dissipation mechanism. Accordingly, fewer microneedles 112 could likely be used. The above specifications are representative only. One of skill in the art will appreciate that the specifications of system 100 may vary depending on the desired application.
System 200 further includes a control unit 210 implanted in the subject. Control unit 210 may be subdermally implanted (e.g., embedded in a subcutaneous fat layer), or may be implanted deeper within patient. Control unit 210 includes a housing 212 that encloses a plurality of electronic components, as described in detail in association with
In some embodiments, control unit 210 may be external to the subject's body (i.e., not subcutaneously implanted). In such embodiments, driveline 214 may extend through skin 102 (e.g., using a connector assembly similar to that shown in
In this embodiment, positive and negative microconductors 202 and 204 are each electrically coupled to a detachable button 220 adhered to skin 102 using a protective barrier 222. Further, each button 220 is electrically coupled to external power source 206 via a power cable 224. Protective barrier 222 may be, for example, an adhesive tape barrier. When a sufficient force is exerted on power cables 224, buttons 220 detach from skin 102 and positive microconductors 202 and 204 to prevent injury to the subject.
First electrical terminal 404 contacts the positive electrical contact of control unit 210 to electrically couple microconductor 400 to control unit 210. As shown in
In this embodiment, positive and negative electrical contacts 704 and 706 each include a metallic mesh 708 (e.g., titanium wool) or highly conductive silicone that is doped with microparticles of metallic silver. Accordingly, positive and negative microconductors 202 and 204 need only contact a portion of the metallic mesh or conductive silicone, as opposed to a discrete electrical contact. This improves ease of implantation and operation of system 200. Each metallic mesh 708 is sintered to a metallic (e.g., titanium) plate 710, which is in turn connected to a feedthrough 712 for electrically coupling to electrical components inside control unit 210. Similarly, in embodiments with conductive silicone, the conductive silicone may be adhered to a metallic (e.g., silver) plate that is in turn connected to a feedthrough for electrically coupling to electrical components inside control unit.
In this embodiment, microconductors 202 and 204 are electrically coupled to a full wave bridge rectifier 720 that receives AC power from positive and negative microconductors 202 and 204 and converts it to DC power for use by control unit 210. This approach simplifies connection of the power source, because when microconductors 202 and 204 conduct AC power, microconductors 202 and 204 may be inserted positive and negative electrical contacts 704 and 706 without any concern about the polarity. Alternatively, as noted above, control unit 210 may receive DC power from positive and negative microconductors 202 and 204. The DC power is regulated using power conditioning circuitry 722 and provided to a microprocessor 724 that controls operation of control unit 210. In this embodiment, power conditioning circuitry also provides power to recharge circuitry 726 for charging a battery 728 within control unit 210. If control unit 210 stops receiving power from external power source 206, battery 728 may temporarily provide power to control unit 210 and the implanted device. Battery 728 may be, for example, a lithium ion battery having a nominal voltage of 3.2 V and a rated capacity of 1150 milliampere hours (mAh). Alternatively, battery 728 may have any specifications that enable control unit 210 to function as described herein. In some embodiments, control unit 210 may not include recharge circuitry 726 and battery 728.
Microprocessor 724 is communicatively coupled to a Bluetooth low energy (BLE) transceiver 730. Using an antenna 732, BLE transceiver 730 is capable of transmitting and receiving signals from a remote device (e.g., an external programmer). For example, antenna 732 may transmit signals to a remote device (e.g., a mobile computing device, a smartphone, a tablet, etc.) to notify the subject and/or physician of problems associated with operation of the implanted device and/or control unit 210 (e.g., cavitation, suction, arrhythmia, excessive pump loading, failure of battery 728, low power from external power source 206, intermittent connectivity with/disconnection from positive and negative microconductors 202 and 204, etc.). For example, antenna 732 may transmit signals to a remote device when an overcurrent condition is detected or fuse circuitry breaks, as described above. The remote device may include a patient's personal smartphone. Further, the remote device may include an application that communications with the patient directly and that communicates with a remote data management system that provides data to health care management personnel and/or a physician to aide in management of the implanted device.
Alternatively, microprocessor 724 may communicate with remote devices using any suitable communications scheme. For example, in some embodiments, microprocessor 724 may communicate conductively (e.g., using amplitude or frequency modulated signals) through microconductors 202 and 204. Further, in some embodiments, driveline 214 may transmit a communication signal (e.g., encoded as an amplitude or frequency modulated signal) on top of the power signal.
Microprocessor 724 is also communicatively coupled to a motor microcontroller 740. Motor microcontroller 740 controls operation of the implanted device (e.g., a VAD, SCS device, and/or DBS device) based on control signals received from microprocessor 724. Specifically, motor microcontroller 740 causes a motor driver 742 to transmit control signals to the implanted device through driveline 214. Driveline 214 also provides power to the implanted device. In this embodiment, motor driver 742 is communicatively coupled to driveline 214 via a plurality of driveline feedthroughs 744 and a driveline connector 746, as shown in
In system 200, control unit 210 is capable of detecting that at least one of positive and negative microconductors 202 and 204 has become disconnected from positive and negative electrical contacts 704 and 706. For example, in one embodiment, power conditioning circuit 722 may include a voltage detection circuit that detects a voltage level delivered by external power source 206. When the voltage drops below a predetermined level, either due to a disconnection or because a battery of external power source 206 has become sufficiently discharged to warrant replacement/recharging, an alert for the patient and/or healthcare provider maybe generated and transmitted using BLE transceiver 730. The voltage level delivered by external power source 206 may be measured by microprocessor 724 using an integral A/D converter. Alternatively, external power source 206 may monitor a voltage drop across a resistor (e.g., 0.1 ohm) in series with external power source 206 to detect when the voltage drop is too low (thus indicating that delivered current is too low or zero).
Further, as described above, safety mechanisms to detect a disconnection may include an overcurrent detector in series with external power source 206, fuse circuitry that breaks when an overcurrent condition occurs, and/or analog switches for each electrical contact point. In response to detecting a disconnection, control unit 210 generates an alert. For example, in one embodiment, control unit 210 generates an audible alert. In another embodiment, control unit 210 vibrates. In yet another embodiment, BLE transceiver 730 causes antenna 732 to transmit an alert signal. Alternatively, control unit 210 may generate any suitable alert. Furthermore, a smartphone or other mobile computing device that receives an alert may transmit the alert to a device management center. The smartphone or other mobile computing device may have an application that instructs the patient how to manage the implanted device (e.g., instructing the patient to replace external power source 206, or to replace microconductors 202 and 204 when a voltage of external power source 206 remains high but a voltage at power conditioning circuit 722 is excessively low. Of course, if system 200 shows signs of failure or malfunction, both the patient and professionals helping the patient manage the implanted device will be notified.
In various embodiments, system 200 includes a resistor for detecting when positive and negative microconductors 202 and 204 and positive and negative electrical contacts 704 and 706 have formed a proper connection. System 200 can thus generate a signal to indicate to a user whether a proper connection has been formed or not. In various embodiments, system 200 includes a mechanism for signaling to a user whether a proper connection has been made. The signal may be visual, audible, or tactile (e.g., control unit 210 may vibrate). System 200 may be configured to generate a signal indicative of whether proper connection has been made. The signal may be transmitted to another component (e.g., a controller). In response, the controller or other component may generate an alarm if an improper connection occurs. The controller may enter a unique mode, such as a low power state or auto shutoff to avoid further consequence. In one embodiment, when an improper connection occurs, power is switched from an external power source to an internal power source.
In the embodiment of
The systems and methods described herein may be used to provide power to any suitable implanted device. For example, the systems and methods described herein may be used in conjunction with devices and systems described in U.S. Patent Publication No. 2015/0290374 filed Apr. 15, 2015, U.S. Patent Publication No. 2015/0290378 filed Apr. 15, 2015, U.S. Pat. No. 6,100,618 filed Oct. 1, 1997, U.S. Pat. No. 6,365,996 filed Feb. 10, 1998, U.S. Pat. No. 5,708,346 filed Jun. 11, 1996, U.S. Pat. No. 8,562,508 filed Dec. 30, 2009, U.S. Pat. No. 8,794,989 filed Dec. 8, 2011, U.S. Pat. No. 8,858,416 filed Aug. 26, 2013, and U.S. Pat. No. 8,682,431 filed Jan. 23, 2013, all of which are hereby incorporated by reference in their entirety.
As an Example,
Mechanical circulatory support system 1110 includes an implantable blood pump 1114, ventricular cuff 1116, outflow cannula 1118, system controller 1120, and power sources 1122. One or more components of system controller 1120 and/or power sources 1122 may be implanted within the subject instead of external to the subject as shown in
In various embodiments, mechanical circulatory support system 1110 is configured for a temporary support mode. In an exemplary embodiment, mechanical circulatory support system 1110 is configured to enable a free mode whereby the patient can be supported for a time free from the external components. Batteries 1122 and control circuitry can be implanted to operate the pump. Connector 1113 facilitates easy disconnection (and reconnection) of the external components. In normal usage, a driveline 1126 is connected through connector 1113. Blood pump 1114 is powered by main batteries or another power source outside body 1112. To convert to free mode, the external portion of driveline 1126 is removed from connector 1113. System 1110 recognizes the disconnection and converts to the free mode by operating using the implanted power source. In some embodiments, the control circuitry includes a state detection module and selects a state based on whether driveline 1126 is connected. For example, in free mode system 1110 can be preprogrammed to operate in a manner to lower the power usage. In various embodiments, connector 1113 is configured as a breakaway connector. Connector 1113 may be configured such that driveline 1126 can be removed only after a force above a selected threshold is applied. Examples of a breakaway connector are described in U.S. Pat. No. 8,794,989 filed Dec. 8, 2011; U.S. Pat. No. 8,894,561 filed Mar. 5, 2013; U.S. Pat. No. 9,387,285 filed Oct. 16, 2015; and U.S. Pat. No. 8,152,035 filed Jul. 6, 2006, the entire contents of which are incorporated herein in their entirety by reference.
With continued reference to
Related controller systems applicable to the systems and methods described herein are described in greater detail in U.S. Pat. Nos. 5,888,242, 6,991,595, 8,323,174, 8,449,444, 8,506,471, 8,597,350, and 8,657,733 and U.S. Patent Publication Nos. 2005/0071001 and 2013/0314047, all of which are incorporated herein by reference for all purposes in their entirety. The system may be powered by either one, two, or more batteries 1122. It will be appreciated that although system controller 1120 and power source 1122 are illustrated outside/external to the subject body, driveline 1126, system controller 1120 and/or power source 1122 may be partially or fully implantable within the patient, as described above in relation to systems 100 and 200, and as separate components or integrated with the blood pump 1114. Examples of such modifications are further described in U.S. Pat. No. 8,562,508 and U.S. Patent Publication No. 2013/0127253, all of which are incorporated herein by reference for all purposes in their entirety.
The systems described herein (e.g., systems 100 and 200) may be configured to generate an alert upon detecting a disconnection of connector 1113 (e.g., disconnection of external connector 104 from internal connector 106 (shown in
To facilitate a temporary support mode, in some embodiments, the systems described herein include an internal power source (e.g., a battery) capable of supplying power for a predetermined period of time. In the temporary support mode, the internal power source may be capable of supporting the patient, for example, for at least twenty minutes, at least thirty minutes, at least forty-five minutes, at least one hour, or at least four hours. Accordingly, the patient could disconnect from external power sources for a period of time (e.g., to take a shower, go for a swim, or participate in other activities that might be difficult or impossible for the patient to undertake without disconnection from external power sources). In some embodiments, the internal power source may be capable of supporting the patient for extended periods of time (e.g., approximately four to six hours).
In various embodiments, a cover is provided to cover connector 1113 when driveline 1126 is disconnected. The cover may comprise a sealing assembly to fluidly seal the electrical contacts of connector 1113 to prevent a short, corrosion, and other issues. The sealing assembly may include, for example, one or more hermetic waterproof seals, hermetic waterproof caps, self-healing membranes, and/or other suitable structures capable of preventing exposure from the contacts to the environment. For example, in system 100, the sealing assembly may be formed, for example, on microwire holder 114, electrical contacts 116, and/or microneedles 112 (all shown in
The systems and methods described herein provide several clinical and technical advantages over at least some known existing transcutaneous power transfer systems. For example, the embodiments described herein use small-diameter conductors to facilitate reducing inflammatory response and risk of infection in a subject. The distribution across a plurality of relatively thin conductors may provide increased redundancy while reducing the amount of current going through each conductor. This can lead to lowering corrosive activity and infection risk. Decreasing the size of the conductors and increasing the number of connections may increase redundancy and mitigate against the risk of a short by faulty connections (e.g., a broken conductor or fluid ingress in the connector). Further, the small-diameter conductors may be replaced and/or relocated periodically to allow previous power transfer sites to heal. Further, as described herein, internal and external components of the transcutaneous power transfer systems described herein are relatively easy to connect and disconnect from one another. For example, in the embodiment shown in
The foregoing descriptions of specific embodiments of the present invention have been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed, and obviously many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and its practical application, to thereby enable others skilled in the art to best utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the Claims appended hereto and their equivalents.
This application claims priority to provisional application Ser. No. 62/447,488, filed Jan. 18, 2017, and provisional application Ser. No. 62/471,494, filed Mar. 15, 2017, both of which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4041955 | Kelly et al. | Aug 1977 | A |
4352960 | Dormer et al. | Oct 1982 | A |
4561443 | Hogrefe et al. | Dec 1985 | A |
4561444 | Livingston et al. | Dec 1985 | A |
4630615 | Yomtov | Dec 1986 | A |
4679560 | Galbraith | Jul 1987 | A |
4726378 | Kaplan | Feb 1988 | A |
4736747 | Drake | Apr 1988 | A |
4924171 | Baba et al. | May 1990 | A |
4945305 | Blood | Jul 1990 | A |
5070223 | Colasante | Dec 1991 | A |
5205286 | Soukup et al. | Apr 1993 | A |
5346458 | Affeld | Sep 1994 | A |
5350413 | Miller et al. | Sep 1994 | A |
5569156 | Mussivand | Oct 1996 | A |
5630836 | Prem et al. | May 1997 | A |
5690693 | Wang et al. | Nov 1997 | A |
5695471 | Wampler | Dec 1997 | A |
5702431 | Wang et al. | Dec 1997 | A |
5708346 | Schoeb | Jan 1998 | A |
5755748 | Borza | May 1998 | A |
5771438 | Palermo et al. | Jun 1998 | A |
5831248 | Hojyo et al. | Nov 1998 | A |
5888242 | Antaki et al. | Mar 1999 | A |
5948006 | Mann | Sep 1999 | A |
6070103 | Ogden | May 2000 | A |
6071093 | Hart | Jun 2000 | A |
6100618 | Schoeb et al. | Aug 2000 | A |
6116862 | Rau et al. | Sep 2000 | A |
6123726 | Mori et al. | Sep 2000 | A |
6149683 | Lancisi et al. | Nov 2000 | A |
6186665 | Maher et al. | Feb 2001 | B1 |
6212430 | Kung | Apr 2001 | B1 |
6234772 | Wampler et al. | May 2001 | B1 |
6264635 | Wampler et al. | Jul 2001 | B1 |
6296533 | Grubbs et al. | Oct 2001 | B1 |
6312338 | Sato et al. | Nov 2001 | B1 |
6320354 | Sengupta et al. | Nov 2001 | B1 |
6324431 | Zarinetchi et al. | Nov 2001 | B1 |
6327504 | Dolgin et al. | Dec 2001 | B1 |
6334856 | Allen | Jan 2002 | B1 |
6365996 | Schob | Apr 2002 | B2 |
6389318 | Zarinetchi et al. | May 2002 | B1 |
6400991 | Kung | Jun 2002 | B1 |
6442434 | Zarinetchi et al. | Aug 2002 | B1 |
6451055 | Weiss | Sep 2002 | B1 |
6458164 | Weiss | Oct 2002 | B1 |
6478820 | Weiss | Nov 2002 | B1 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6579315 | Weiss | Jun 2003 | B1 |
6591139 | Loftin et al. | Jul 2003 | B2 |
6605032 | Benkowski et al. | Aug 2003 | B2 |
6647298 | Abrahamson et al. | Nov 2003 | B2 |
6650213 | Sakurai et al. | Nov 2003 | B1 |
6688861 | Wampler | Feb 2004 | B2 |
6723039 | French et al. | Apr 2004 | B2 |
6772011 | Dolgin | Aug 2004 | B2 |
6801807 | Abrahamson | Oct 2004 | B2 |
6810289 | Shaquer | Oct 2004 | B1 |
6850803 | Jimenez et al. | Feb 2005 | B1 |
6894456 | Tsukamoto et al. | May 2005 | B2 |
6895281 | Amundson et al. | May 2005 | B1 |
6949065 | Sporer et al. | Sep 2005 | B2 |
6960968 | Odenaal et al. | Nov 2005 | B2 |
6967621 | Cadotte, Jr. et al. | Nov 2005 | B1 |
6985773 | Von Arx et al. | Jan 2006 | B2 |
6991595 | Burke et al. | Jan 2006 | B2 |
7015769 | Schulman et al. | Mar 2006 | B2 |
7107103 | Schulman et al. | Sep 2006 | B2 |
7126310 | Barron | Oct 2006 | B1 |
7225032 | Schmeling et al. | May 2007 | B2 |
7246040 | Borg et al. | Jul 2007 | B2 |
7286880 | Olson et al. | Oct 2007 | B2 |
7428438 | Parramon et al. | Sep 2008 | B2 |
7471986 | Hatlestad | Dec 2008 | B2 |
7496733 | Altman et al. | Feb 2009 | B2 |
7505816 | Schmeling et al. | Mar 2009 | B2 |
7515012 | Schulman et al. | Apr 2009 | B2 |
7522878 | Baarman | Apr 2009 | B2 |
7532901 | Lafranchise et al. | May 2009 | B1 |
7565187 | Dynok et al. | Jul 2009 | B1 |
7571007 | Erickson et al. | Aug 2009 | B2 |
7574173 | Terranova et al. | Aug 2009 | B2 |
7587241 | Parramon et al. | Sep 2009 | B2 |
7599743 | Hassler, Jr. et al. | Oct 2009 | B2 |
7650187 | Gruber et al. | Jan 2010 | B2 |
7650192 | Wahlstrand | Jan 2010 | B2 |
7699586 | Larose et al. | Apr 2010 | B2 |
7711433 | Davis et al. | May 2010 | B2 |
7720546 | Ginggen et al. | May 2010 | B2 |
7741734 | Joannopoulos et al. | Jun 2010 | B2 |
7761164 | Verhoef et al. | Jul 2010 | B2 |
7774069 | Olson et al. | Aug 2010 | B2 |
7782190 | Martin et al. | Aug 2010 | B1 |
7805200 | Kast et al. | Sep 2010 | B2 |
7812481 | Iisaka et al. | Oct 2010 | B2 |
7818036 | Lair et al. | Oct 2010 | B2 |
7818037 | Lair et al. | Oct 2010 | B2 |
7825543 | Karalis et al. | Nov 2010 | B2 |
7830114 | Reed | Nov 2010 | B2 |
7865245 | Torgerson et al. | Jan 2011 | B2 |
7872367 | Recksiek et al. | Jan 2011 | B2 |
7904170 | Harding | Mar 2011 | B2 |
7932696 | Peterson et al. | Apr 2011 | B2 |
7962222 | He et al. | Jun 2011 | B2 |
7976271 | Larose et al. | Jul 2011 | B2 |
7997854 | Larose et al. | Aug 2011 | B2 |
8007254 | Larose et al. | Aug 2011 | B2 |
RE42682 | Barreras et al. | Sep 2011 | E |
8062783 | Carter et al. | Nov 2011 | B2 |
8076807 | Roland et al. | Dec 2011 | B2 |
8081925 | Parramon et al. | Dec 2011 | B2 |
8096954 | Stahmann et al. | Jan 2012 | B2 |
8140168 | Olson et al. | Mar 2012 | B2 |
8150529 | Snell et al. | Apr 2012 | B2 |
8152493 | Larose et al. | Apr 2012 | B2 |
8165694 | Carbanaru et al. | Apr 2012 | B2 |
8185212 | Carbunaru et al. | May 2012 | B2 |
8193766 | Rondoni et al. | Jun 2012 | B2 |
8203434 | Yoshida | Jun 2012 | B2 |
8244367 | Wahlstrand et al. | Aug 2012 | B2 |
8247926 | Issa et al. | Aug 2012 | B2 |
8258653 | Kitamura et al. | Sep 2012 | B2 |
8265770 | Toy et al. | Sep 2012 | B2 |
8278784 | Cook et al. | Oct 2012 | B2 |
8292052 | Bohori et al. | Oct 2012 | B2 |
8299652 | Smith et al. | Oct 2012 | B2 |
8301079 | Baarman | Oct 2012 | B2 |
8319473 | Choi et al. | Nov 2012 | B2 |
8323174 | Jeevanandam et al. | Dec 2012 | B2 |
8362742 | Kallmyer | Jan 2013 | B2 |
8373310 | Baarman et al. | Feb 2013 | B2 |
8378522 | Cook et al. | Feb 2013 | B2 |
8378523 | Cook et al. | Feb 2013 | B2 |
8449444 | Poirier | May 2013 | B2 |
8463395 | Forsell | Jun 2013 | B2 |
8489200 | Zarinetchi et al. | Jul 2013 | B2 |
8506471 | Bourque | Aug 2013 | B2 |
8545436 | Robertson et al. | Oct 2013 | B2 |
8551163 | Aber et al. | Oct 2013 | B2 |
8562508 | Dague et al. | Oct 2013 | B2 |
8581793 | Carr | Nov 2013 | B2 |
8587154 | Fells et al. | Nov 2013 | B2 |
8588884 | Hegde et al. | Nov 2013 | B2 |
8597350 | Rudser et al. | Dec 2013 | B2 |
8620447 | D'Ambrosio et al. | Dec 2013 | B2 |
8628460 | Yomtov et al. | Jan 2014 | B2 |
8629578 | Kurs et al. | Jan 2014 | B2 |
8652024 | Yanai et al. | Feb 2014 | B1 |
8657733 | Ayre et al. | Feb 2014 | B2 |
8668473 | Larose et al. | Mar 2014 | B2 |
8682431 | Callaway et al. | Mar 2014 | B2 |
8694117 | Aghassian et al. | Apr 2014 | B2 |
8794989 | Kearsley et al. | Aug 2014 | B2 |
8810071 | Sauerlaender et al. | Aug 2014 | B2 |
8858416 | Crosby et al. | Oct 2014 | B2 |
8884468 | Lemmens et al. | Nov 2014 | B2 |
8909351 | Dinsmoor et al. | Dec 2014 | B2 |
8971958 | Frikart et al. | Mar 2015 | B2 |
9002468 | Shea et al. | Apr 2015 | B2 |
9091271 | Bourque | Jul 2015 | B2 |
9106083 | Partovi | Aug 2015 | B2 |
9114238 | Singh et al. | Aug 2015 | B2 |
9149331 | Deem et al. | Oct 2015 | B2 |
9166347 | Sabin et al. | Oct 2015 | B2 |
9192704 | Yomtov et al. | Nov 2015 | B2 |
9302093 | Mashiach | Apr 2016 | B2 |
9515494 | Kurs et al. | Dec 2016 | B2 |
9515495 | Kurs et al. | Dec 2016 | B2 |
9560787 | Kallmyer et al. | Jan 2017 | B2 |
10388142 | Kimball | Aug 2019 | B2 |
20020038138 | Zarinetchi et al. | Mar 2002 | A1 |
20020087204 | Kung et al. | Jul 2002 | A1 |
20020093456 | Sawamura et al. | Jul 2002 | A1 |
20020138049 | Allen | Sep 2002 | A1 |
20030171792 | Zarinetchi et al. | Sep 2003 | A1 |
20040138725 | Forsell | Jul 2004 | A1 |
20040256146 | Frericks et al. | Dec 2004 | A1 |
20050006083 | Chen et al. | Jan 2005 | A1 |
20050071001 | Jarvik | Mar 2005 | A1 |
20050090883 | Westlund et al. | Apr 2005 | A1 |
20050288743 | Ahn et al. | Dec 2005 | A1 |
20060199997 | Hassler et al. | Sep 2006 | A1 |
20060271129 | Tai et al. | Nov 2006 | A1 |
20070078293 | Shambaugh, Jr. et al. | Apr 2007 | A1 |
20070096686 | Jimenez et al. | May 2007 | A1 |
20070123948 | Dal Molin | May 2007 | A1 |
20070142696 | Crosby et al. | Jun 2007 | A1 |
20070191706 | Calderon et al. | Aug 2007 | A1 |
20080009198 | Marino | Jan 2008 | A1 |
20080021394 | Larose et al. | Jan 2008 | A1 |
20080027293 | Vodermayer et al. | Jan 2008 | A1 |
20080054638 | Greene et al. | Mar 2008 | A1 |
20080100294 | Rohling et al. | May 2008 | A1 |
20080149736 | Kim et al. | Jun 2008 | A1 |
20080167531 | McDermott | Jul 2008 | A1 |
20080211320 | Cook et al. | Sep 2008 | A1 |
20090018616 | Quick et al. | Jan 2009 | A1 |
20090051224 | Cook et al. | Feb 2009 | A1 |
20090072628 | Cook et al. | Mar 2009 | A1 |
20090081943 | Dobyns et al. | Mar 2009 | A1 |
20090174264 | Onishi et al. | Jul 2009 | A1 |
20090203957 | Larose et al. | Aug 2009 | A1 |
20090212736 | Baarman et al. | Aug 2009 | A1 |
20090226328 | Morello | Sep 2009 | A1 |
20090270679 | Hoeg et al. | Oct 2009 | A1 |
20090284220 | Toncich et al. | Nov 2009 | A1 |
20100019985 | Bashyam et al. | Jan 2010 | A1 |
20100033021 | Bennett | Feb 2010 | A1 |
20100035453 | Tronnes et al. | Feb 2010 | A1 |
20100045114 | Sample et al. | Feb 2010 | A1 |
20100063347 | Yomtov et al. | Mar 2010 | A1 |
20100066305 | Takahashi et al. | Mar 2010 | A1 |
20100069992 | Aghassian et al. | Mar 2010 | A1 |
20100109958 | Haubrich et al. | May 2010 | A1 |
20100114143 | Albrecht et al. | May 2010 | A1 |
20100122995 | Thomas et al. | May 2010 | A1 |
20100171368 | Schatz et al. | Jul 2010 | A1 |
20100184371 | Cook et al. | Jul 2010 | A1 |
20100194334 | Kirby et al. | Aug 2010 | A1 |
20100210233 | Cook et al. | Aug 2010 | A1 |
20100211134 | Forsell | Aug 2010 | A1 |
20100222848 | Forsell | Sep 2010 | A1 |
20100222849 | Forsell | Sep 2010 | A1 |
20100225174 | Jiang | Sep 2010 | A1 |
20100244576 | Hillan et al. | Sep 2010 | A1 |
20100253340 | Corum et al. | Oct 2010 | A1 |
20100256708 | Thornton et al. | Oct 2010 | A1 |
20100262135 | Berube | Oct 2010 | A1 |
20100277121 | Hall et al. | Nov 2010 | A1 |
20100308939 | Kurs | Dec 2010 | A1 |
20100314946 | Budde et al. | Dec 2010 | A1 |
20100331919 | Digiore et al. | Dec 2010 | A1 |
20110025132 | Sato | Feb 2011 | A1 |
20110043050 | Yabe et al. | Feb 2011 | A1 |
20110046699 | Mazanec et al. | Feb 2011 | A1 |
20110101790 | Budgett | May 2011 | A1 |
20110109263 | Sakoda et al. | May 2011 | A1 |
20110115431 | Dunworth et al. | May 2011 | A1 |
20110127848 | Ryu et al. | Jun 2011 | A1 |
20110148215 | Marzetta et al. | Jun 2011 | A1 |
20110178361 | Yomtov | Jul 2011 | A1 |
20110181235 | Walley et al. | Jul 2011 | A1 |
20110205083 | Janna et al. | Aug 2011 | A1 |
20110234011 | Yi et al. | Sep 2011 | A1 |
20110234155 | Chen et al. | Sep 2011 | A1 |
20110241436 | Furukawa | Oct 2011 | A1 |
20110241750 | Hill | Oct 2011 | A1 |
20110245892 | Kast et al. | Oct 2011 | A1 |
20110266880 | Kim et al. | Nov 2011 | A1 |
20110276110 | Whitehurst et al. | Nov 2011 | A1 |
20110278948 | Forsell | Nov 2011 | A1 |
20110291489 | Tsai et al. | Dec 2011 | A1 |
20110291613 | Rosik et al. | Dec 2011 | A1 |
20110295345 | Wells et al. | Dec 2011 | A1 |
20110298294 | Takada et al. | Dec 2011 | A1 |
20110301667 | Olson et al. | Dec 2011 | A1 |
20110313238 | Reichenbach et al. | Dec 2011 | A1 |
20120001485 | Uchida | Jan 2012 | A1 |
20120032522 | Schatz et al. | Feb 2012 | A1 |
20120039102 | Shinoda | Feb 2012 | A1 |
20120046514 | Bourque | Feb 2012 | A1 |
20120057322 | Waffenschmidt | Mar 2012 | A1 |
20120065458 | Tol | Mar 2012 | A1 |
20120080957 | Cooper et al. | Apr 2012 | A1 |
20120091951 | Sohn | Apr 2012 | A1 |
20120095281 | Reichenbach et al. | Apr 2012 | A1 |
20120104997 | Carobolante | May 2012 | A1 |
20120109256 | Meskins et al. | May 2012 | A1 |
20120119914 | Uchida | May 2012 | A1 |
20120146575 | Armstrong et al. | Jun 2012 | A1 |
20120149229 | Kearsley et al. | Jun 2012 | A1 |
20120150259 | Meskens | Jun 2012 | A1 |
20120153739 | Cooper et al. | Jun 2012 | A1 |
20120153954 | Ota et al. | Jun 2012 | A1 |
20120157753 | D'Ambrosio | Jun 2012 | A1 |
20120157754 | D'Ambrosio | Jun 2012 | A1 |
20120158407 | Forsell | Jun 2012 | A1 |
20120161539 | Kim et al. | Jun 2012 | A1 |
20120164943 | Bennett | Jun 2012 | A1 |
20120169132 | Choudhary et al. | Jul 2012 | A1 |
20120169133 | Lisi et al. | Jul 2012 | A1 |
20120169137 | Lisi et al. | Jul 2012 | A1 |
20120169139 | Kudo | Jul 2012 | A1 |
20120169278 | Choi et al. | Jul 2012 | A1 |
20120175967 | Dibben et al. | Jul 2012 | A1 |
20120235364 | Wang et al. | Sep 2012 | A1 |
20120239118 | Ozawa et al. | Sep 2012 | A1 |
20120245649 | Bohori et al. | Sep 2012 | A1 |
20120245664 | Smith et al. | Sep 2012 | A1 |
20120259398 | Chen et al. | Oct 2012 | A1 |
20120274148 | Sung et al. | Nov 2012 | A1 |
20120306433 | Kim et al. | Dec 2012 | A1 |
20130007949 | Kurs et al. | Jan 2013 | A1 |
20130060103 | Bergida et al. | Mar 2013 | A1 |
20130096364 | Reichenbach et al. | Apr 2013 | A1 |
20130096602 | Kumar | Apr 2013 | A1 |
20130119773 | Davis | May 2013 | A1 |
20130121821 | Ozaki et al. | May 2013 | A1 |
20130127253 | Stark et al. | May 2013 | A1 |
20130149960 | Dec et al. | Jun 2013 | A1 |
20130159956 | Verghese et al. | Jun 2013 | A1 |
20130170970 | Ozaki et al. | Jul 2013 | A1 |
20130190551 | Callaway et al. | Jul 2013 | A1 |
20130197607 | Wilder et al. | Aug 2013 | A1 |
20130204316 | Carpentier | Aug 2013 | A1 |
20130214731 | Dinsmoor et al. | Aug 2013 | A1 |
20130225909 | Dormanen et al. | Aug 2013 | A1 |
20130241306 | Aber et al. | Sep 2013 | A1 |
20130241468 | Moshfeghi | Sep 2013 | A1 |
20130271088 | Hwang et al. | Oct 2013 | A1 |
20130289334 | Badstibner et al. | Oct 2013 | A1 |
20130303020 | Sabin et al. | Nov 2013 | A1 |
20130310630 | Smith et al. | Nov 2013 | A1 |
20130314047 | Eagle et al. | Nov 2013 | A1 |
20130320773 | Schatz et al. | Dec 2013 | A1 |
20130331638 | Cameron et al. | Dec 2013 | A1 |
20140005466 | Crosby et al. | Jan 2014 | A1 |
20140011447 | Konanur et al. | Jan 2014 | A1 |
20140028110 | Petersen et al. | Jan 2014 | A1 |
20140028111 | Hansen et al. | Jan 2014 | A1 |
20140031606 | Hansen et al. | Jan 2014 | A1 |
20140073839 | Yomtov et al. | Mar 2014 | A1 |
20140152252 | Wood | Jun 2014 | A1 |
20140163644 | Scott et al. | Jun 2014 | A1 |
20140265620 | Hoarau et al. | Sep 2014 | A1 |
20140265621 | Wong et al. | Sep 2014 | A1 |
20140275727 | Bonde et al. | Sep 2014 | A1 |
20140324113 | Savage | Oct 2014 | A1 |
20150123654 | Gagnon et al. | May 2015 | A1 |
20150141910 | Francis | May 2015 | A1 |
20150207330 | Petersen | Jul 2015 | A1 |
20150207331 | Petersen | Jul 2015 | A1 |
20150222127 | Hansen et al. | Aug 2015 | A1 |
20150222128 | Hansen | Aug 2015 | A1 |
20150222139 | Petersen et al. | Aug 2015 | A1 |
20150229289 | Suzuki | Aug 2015 | A1 |
20150290373 | Rudser et al. | Oct 2015 | A1 |
20150290374 | Bourque et al. | Oct 2015 | A1 |
20150290378 | Schade et al. | Oct 2015 | A1 |
20160064117 | Romero et al. | Mar 2016 | A1 |
20160135684 | Kappel et al. | May 2016 | A1 |
20160218432 | Pope et al. | Jul 2016 | A1 |
20160250484 | Nguyen et al. | Sep 2016 | A1 |
20160254703 | Hansen | Sep 2016 | A1 |
20160254704 | Hansen et al. | Sep 2016 | A1 |
20170246440 | Kalghatgi | Aug 2017 | A1 |
20180256801 | Conyers | Sep 2018 | A1 |
Number | Date | Country |
---|---|---|
202012000166 | Jun 2013 | DE |
102012201073 | Jul 2013 | DE |
0589608 | Mar 1994 | EP |
1513241 | Mar 2005 | EP |
2267864 | Dec 2010 | EP |
2878060 | Jun 2015 | EP |
2477034 | Jul 2011 | GB |
H03109063 | May 1991 | JP |
11506646 | Jun 1999 | JP |
2013094456 | May 2013 | JP |
2013161640 | Aug 2013 | JP |
2014160611 | Sep 2014 | JP |
1020020089605 | Nov 2002 | KR |
1020120077448 | Jul 2012 | KR |
1020120007296 | Oct 2012 | KR |
0001442 | Jan 2000 | WO |
0074747 | Dec 2000 | WO |
0137926 | May 2001 | WO |
2005106901 | Nov 2005 | WO |
2007053881 | May 2007 | WO |
2008066941 | Jun 2008 | WO |
2009018271 | Feb 2009 | WO |
2009021220 | Feb 2009 | WO |
2009023905 | Feb 2009 | WO |
2009042977 | Apr 2009 | WO |
2010030378 | Mar 2010 | WO |
2010089354 | Aug 2010 | WO |
2011081626 | Jul 2011 | WO |
2011113934 | Sep 2011 | WO |
2012002063 | Jan 2012 | WO |
2012056365 | May 2012 | WO |
2012087807 | Jun 2012 | WO |
2012087811 | Jun 2012 | WO |
2012087816 | Jun 2012 | WO |
2012087819 | Jun 2012 | WO |
2012099965 | Jul 2012 | WO |
2012141752 | Oct 2012 | WO |
2013110602 | Aug 2013 | WO |
2013138451 | Sep 2013 | WO |
2014018965 | Jan 2014 | WO |
2014039673 | Mar 2014 | WO |
Entry |
---|
Bonde et al.; Promise of unrestricted mobility with innovative, portable wireless powering of a mechanical circulatory assist device; American Association for Thoracic Surgery; ©2012; 2 pgs.; retrieved Mar. 12, 2014 from the internet: http://aats.org/annualmeeting/Abstracts/2012/T8.cgi. |
Chargepoint, Inc.; -chargepoin+®; product brochure; 4 pgs.; ©2014; retrieved Mar. 12, 2014 from the internet: http://www.chargepoint.com/network/. |
Dixon, Jr.; Eddy current losses in transformer windings and circuit wiring; Unitrode Corp. Seminar Manual (SEM600): Watertown, MA; 12 pgs.; 1988 (year of pub. sufficiently earlier than effective US filing date and any foreign priority date). |
Evatran; PluglessTM Level 2 EV Charging System (3.3kW); product brochure; 7 pgs.; retrieved Mar. 12, 2014 from the internet: http://www.pluglesspower.com/tech-specs/. |
Ferret, B.; Electric vehicles get big boost!; Renewable Energy World; 3 pgs.; Jul. 30, 2012; retrieved Jul. 30, 2012 from the internet: http://www.renewableenergyworld.com/rea/blog/post/2012/07/. |
Motavalli, Jim; WiTricity Takes Its Car-Charging Technology Out for a Road Test; New York Times; 3 pgs.; Jul. 25, 2012; retrieved Mar. 12, 2014 from the internet: http://wheels.blogs.nytimes.com/2012/07/25/witricity-takes-its-car-charging-technology-out-for-a-road-test/. |
Notification of Transmittal of the international Search Report and the Written Opinion of the International Searching Authority for PCT Application No. PCT/US2015/051474, dated Dec. 30, 2015. |
Development and Implementation of RFID Technology, Ed. Cristina Turcu, Feb. 2009, pp. 28-30, 93-97. |
Merli, Francesco, et al., “Design, Realization and Measurements of a Miniature Antenna for Implantable Wireless Communication Systems”, IEEE Transaction on Antennas and Propagation, vol. 59, No. 10, Oct. 2011, pp. 3544-3555. |
Merli, Francesco, et al.,“ The Effect of Insulating Layers on the Performance of Implanted Antennas”, IEEE Transaction on Antennas and Propagation, vol. 59, No. 1, Jan. 2011, pp. 21-31. |
Abadia, Javier, et al., 3D-Spiral Small Antenna Design and Realization for Biomdical Telemetry in the MICS Band. Radioengineering, vol. 18, No. 4, Dec. 2009, pp. 359-367. |
Panasonic Lithium Ion UF553450Z Spec Sheet, 1 page. |
Moazami, et al. Pump Replacement for Left Ventricular Assist Device Failure Can be Done Safely and Is Associated with Low Mortality. Ann Thorac Surg 2013;95;500-505. |
Kalavrouziotis D., et al.“Incidence and characterization of percutaneous lead damage in the Heartmate II left ventricular assist device” J Heart and Lung Transplantation 2013:32(4);S85. |
http://www.mdpi.com/pharmaceutics/pharmaceutics-06-00220/article_deploy/html/images/pharmaceutics-06-00220-g001-1024.png. |
International Search Report and Written Opinion for International Patent Application No. PCT/US2018/014150, dated Aug. 8, 2018, 16 pages. |
Number | Date | Country | |
---|---|---|---|
20180200423 A1 | Jul 2018 | US |
Number | Date | Country | |
---|---|---|---|
62471494 | Mar 2017 | US | |
62447488 | Jan 2017 | US |